Short QT syndrome screening: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
<nowiki>[[Short QT syndrome]]</nowiki> is an autosomal dominant inherited disease, and having a family member with the disease places an individual at risk for the disease.  Family members of affected individuals should, therefore, be screened.  New-onset [[lone atrial fibrillation]] may be a marker of the disease, and young patients with [[lone atrial fibrillation]] should be screened as well.  Short QT syndrome should be excluded in patients without structural heart disease presenting with sudden cardiac death.
Short QT syndrome is an autosomal dominant inherited disease, and having a family member with the disease places an individual at risk for the disease.  Family members of affected individuals should, therefore, be screened.  New-onset [[lone atrial fibrillation]] may be a marker of the disease, and young patients with [[lone atrial fibrillation]] should be screened as well.  Short QT syndrome should be excluded in patients without structural heart disease presenting with sudden cardiac death.
===Screening===
===Screening===
There is insufficient evidence to recommend routine screening for [[Short QT syndrome]]. In the year 2011, The Heart Rhythm Society and the European Heart Rhythm Association have produced an expert consensus statement on genetic testing of channelopathies including SQTS. They recommend genetic testing to be conducted by a cardiologist who has a strong clinical suspicion of SQTS based on history, physical examination, family history, and electrocardiographic findings (grade IIb). Mutation-specific genetic testing is recommended for family members and appropriate relatives following the identification of the SQTS-causative mutation in an index case (grade I)<ref name="pmid21787999">{{cite journal| author=Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H | display-authors=etal| title=HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). | journal=Heart Rhythm | year= 2011 | volume= 8 | issue= 8 | pages= 1308-39 | pmid=21787999 | doi=10.1016/j.hrthm.2011.05.020 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21787999  }} </ref>.New-onset <nowiki>[[lone atrial fibrillation]]</nowiki> may be a marker of the disease, and young patients with <nowiki>[[lone atrial fibrillation]]</nowiki> should be screened as well. Short QT syndrome should be excluded in patients without structural heart disease presenting with sudden cardiac death.
There is insufficient evidence to recommend routine screening for [[Short QT syndrome]]. In the year 2011, The Heart Rhythm Society and the European Heart Rhythm Association have produced an expert consensus statement on genetic testing of channelopathies including SQTS. They recommend genetic testing to be conducted by a cardiologist who has a strong clinical suspicion of SQTS based on history, physical examination, family history, and electrocardiographic findings (grade IIb). Mutation-specific genetic testing is recommended for family members and appropriate relatives following the identification of the SQTS-causative mutation in an index case (grade I)<ref name="pmid21787999">{{cite journal| author=Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H | display-authors=etal| title=HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). | journal=Heart Rhythm | year= 2011 | volume= 8 | issue= 8 | pages= 1308-39 | pmid=21787999 | doi=10.1016/j.hrthm.2011.05.020 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21787999  }} </ref>.New-onset lone atrial fibrillation may be a marker of the disease, and young patients with lone atrial fibrillation should be screened as well. Short QT syndrome should be excluded in patients without structural heart disease presenting with sudden cardiac death.
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Revision as of 13:30, 22 June 2020

Short QT syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Type 1
Type 2
Type 3
Type 4
Type 5

Pathophysiology

Causes

Triggers

Differentiating Short QT syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

EP studies

Genetic Testing

Treatment

AICD Placement

Medical Therapy

Case Studies

Case #1

Short QT syndrome screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Short QT syndrome screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Short QT syndrome screening

CDC on Short QT syndrome screening

Short QT syndrome screening in the news

Blogs on Short QT syndrome screening

Directions to Hospitals Treating Short QT syndrome

Risk calculators and risk factors for Short QT syndrome screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Short QT syndrome is an autosomal dominant inherited disease, and having a family member with the disease places an individual at risk for the disease. Family members of affected individuals should, therefore, be screened. New-onset lone atrial fibrillation may be a marker of the disease, and young patients with lone atrial fibrillation should be screened as well. Short QT syndrome should be excluded in patients without structural heart disease presenting with sudden cardiac death.

Screening

There is insufficient evidence to recommend routine screening for Short QT syndrome. In the year 2011, The Heart Rhythm Society and the European Heart Rhythm Association have produced an expert consensus statement on genetic testing of channelopathies including SQTS. They recommend genetic testing to be conducted by a cardiologist who has a strong clinical suspicion of SQTS based on history, physical examination, family history, and electrocardiographic findings (grade IIb). Mutation-specific genetic testing is recommended for family members and appropriate relatives following the identification of the SQTS-causative mutation in an index case (grade I)[1].New-onset lone atrial fibrillation may be a marker of the disease, and young patients with lone atrial fibrillation should be screened as well. Short QT syndrome should be excluded in patients without structural heart disease presenting with sudden cardiac death.

References

  1. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H; et al. (2011). "HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA)". Heart Rhythm. 8 (8): 1308–39. doi:10.1016/j.hrthm.2011.05.020. PMID 21787999.